Ballicules.com

Nimodipine

NIMOTOP

What it isDihydropyridine calcium channel blocker with cerebral selectivity; aneurysmal subarachnoid hemorrhage.

Why this oneIt improves neurological outcome after subarachnoid hemorrhage, which no other agent does.

What limits it⚑ Never give it intravenously: cardiac arrest and death have occurred. Hypotension can interrupt the required 21-day course.

FDA-approved for

FDA label

BOXED WARNING Do not administer intravenously or by other parenteral routes — deaths and serious/life-threatening events have occurred when capsule contents were injected parenterally.
FDA dosingPopulationStartTargetMax
Subarachnoid hemorrhage (improve neurologic outcome)adult60 mg q4h × 21 days60 mg q4h

Renal Undefined

Hepatic Reduce to 30 mg q4h in cirrhosis/severe hepatic impairment with close BP and HR monitoring

60 mg every 4 hours for 21 consecutive days

Instructions

Contraindications

Cautions

Adverse reactions

Pregnancy Category C; animal teratogenicity; use only if potential benefit justifies risk

Lactation Undefined

⚠ BOXED WARNING

Cost, est. cash$10–$500/month

Generic entry2007

Classes and tags

Clinical profile

Therapeutic safety burden2 / 4
Overdose danger4 / 4
Weight-gain liability0 / 4
Sedation liability0 / 4
QT / Torsades0 / 4
Direct muscarinic antagonism0 / 4
Embryofetal risk1 / 4

Legacy pregnancy categoryC

Defining liabilityHypotension and edema therapeutically; overdose can cause prolonged vasodilatory or cardiogenic shock.

Mechanism of action: Nimodipine ballicule

Nimodipine ballicule: receptor binding, kinetics and half-life diagram

Open Nimodipine in the interactive console ↗

Memory aids: mascots and interaction avatars

Nimodipine NIMOTOP mascot mnemonic cartoon
“Nemo dipping”
Approved for subarachnoid hemorrhage
Nimodipine CYP3A4 substrate avatar
CYP3A4 substrate

Open Nimodipine in the interactive console ↗